April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Evaluation of complement activity in wild type, C5 knockout and humanized mice for drug discovery
Author Affiliations & Notes
  • Adrianna Latuszek
    Ophthalmology, Regeneron Pharmaceuticals, Inc., Tarrytown, NY
  • Ying Hu
    Ophthalmology, Regeneron Pharmaceuticals, Inc., Tarrytown, NY
  • Jingtai Cao
    Ophthalmology, Regeneron Pharmaceuticals, Inc., Tarrytown, NY
  • Stanley J Wiegand
    Ophthalmology, Regeneron Pharmaceuticals, Inc., Tarrytown, NY
  • George D Yancopoulos
    Regeneron Pharmaceuticals, Inc, Tarrytown, NY
  • Footnotes
    Commercial Relationships Adrianna Latuszek, Regeneron Pharmaceuticals, Inc (E); Ying Hu, E (E); Jingtai Cao, Regeneron Pharmaceuticals, Inc (E); Stanley Wiegand, Regeneron Pharmaceuticals, Inc (E); George Yancopoulos, Regeneron Pharmaceuticals, Inc (S)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 1324. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Adrianna Latuszek, Ying Hu, Jingtai Cao, Stanley J Wiegand, George D Yancopoulos; Evaluation of complement activity in wild type, C5 knockout and humanized mice for drug discovery. Invest. Ophthalmol. Vis. Sci. 2014;55(13):1324.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Complement has been implicated in ocular inflammatory and retinal degenerative diseases. Blocking C5 cleavage by monoclonal antibody (mAb) is a possible therapeutic strategy for these disorders. The present study was undertaken to better understand the complement activity in mouse vs. human, and setup a system that could further evaluate the function of candidate therapeutic mAbs in vitro and in vivo.

Methods: Serum was collected from wild type (WT) mice; complement component knockout mice; C5-/-, C3-/-, and humanized C5 mice (C5hu/hu), all generated with Velocigene technology (Regeneron). Hemolytic assay (CH50) was used to assess the functional activity of the complement system. Normal, C3 or C5-depleted human serum (Quidel Corp.) was used for comparison. Human C3 (400 μg/ml), C5 (50 μg/ml) or murine C5 protein (50 μg/ml) was added to test if it could restore the hemolysis function. Anti-human C5 mAb (10 μg/ml) and anti-mouse C5 mAb (10 μg/ml) were used to confirm the specificity and utility of this system for future drug discovery.

Results: WT mouse sera have approximately 10 times lower complement activity compared to human. Sera from C5-/- and C3-/- mice show lack of complement activity. C5hu/hu mouse serum displays no hemolytic activity and is equivalent to serum from complement component deficient mice. The addition of mouse C5 to C5hu/hu mouse serum rescued hemolysis function. Anti-mouse C5 mAb blocked hemolysis in normal mouse serum. Anti-human C5 mAb blocked hemolysis in normal human serum but not in mouse serum. Hemolysis could not be recovered by adding human C5 to C5-/- mouse serum, whereas the addition of human C3 and C5 together rescued hemolysis in C5-/- mouse serum. Addition of human C3 to C5hu/hu mouse serum rescued hemolysis function.

Conclusions: Our findings demonstrate that wild type mice have dramatically lower complement activity compared to human. Transgenic mice expressing human C5 are functional murine C5 knockouts, possibly because mouse convertase cannot cleave human C5. Our results indicate that C3 and C5 double humanized mouse would have complement activity similar to WT and be able to test human Abs.

Keywords: 504 drusen • 659 protein structure/function  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×